| Thu, Jul 9, 2009 | | • | BridgewaterEquity.com Free Fundamental Sector & Market Research on STX, LKQX, EZPW, CSUN, EXEL and CLWR
Marketwire (Thu 7:32am)
| | Wed, Jul 8, 2009 | | • | 15 Overvalued Small Caps from Russell 2000
at Seeking Alpha (Wed, Jul 8)
| | Tue, Jun 30, 2009 | | • | One-Drug Wonders Deserve a Spot in Your Portfolio
at Motley Fool (Tue, Jun 30)
| | Mon, Jun 29, 2009 | | • | Funding From an Unlikely Place
at Motley Fool (Mon, Jun 29)
| | Fri, Jun 26, 2009 | | • | Top-Rated Stocks That Treat Shareholders Right
at Motley Fool (Fri, Jun 26)
| | Mon, Jun 22, 2009 | | • | Dendreon: Cash Out or Keep Riding Up?
at Motley Fool (Mon, Jun 22)
| | Wed, Jun 17, 2009 | | • | Coverage initiated on Exelixis by Boenning & Scattergood
Briefing.com (Wed, Jun 17)
| | Tue, Jun 16, 2009 | | • | Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference
Business Wire (Tue, Jun 16)
| | • | Tomorrow's Monster Stocks
at Motley Fool (Tue, Jun 16)
| | Mon, Jun 15, 2009 | | • | A Big Upgrade for Exelixis
at Motley Fool (Mon, Jun 15)
| | Thu, Jun 4, 2009 | | • | Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference
Business Wire (Thu, Jun 4)
| | Wed, Jun 3, 2009 | | • | Lightning Round OT: Arch Coal, Exelixis and More
at CNBC (Wed, Jun 3)
| | • | 5 Stocks Bucking the Downtrend
at Motley Fool (Wed, Jun 3)
| | • | TiVo, First Financial Bancorp and Isle of Capri Casinos lead small-cap volume in pre-market
SmallCapInvestor.com (Wed, Jun 3)
| | • | Keryx: Another Beneficiary of the ASCO Effect
at Seeking Alpha (Wed, Jun 3)
| | Mon, Jun 1, 2009 | | • | Exelixis ASCO Investor and Analyst Briefing Call scheduled for 6:30 pm ET today
CCBN (Mon, Jun 1)
| | • | 5-Star Stocks on the Upswing
at Motley Fool (Mon, Jun 1)
| | • | Exelixis falls on new data for brain cancer drug
AP (Mon, Jun 1)
| | • | Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR
Business Wire (Mon, Jun 1)
| | • | Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K
Business Wire (Mon, Jun 1)
|
Add EXEL News to My Yahoo!:
 
| |
|
0.06% Nasdaq 0.00%
Headlines
